Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2024 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2024.2391553
Abstract: Abstract Objective Talquetamab is the first GPRC5D-targeting bispecific antibody approved for the treatment of triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). This matching-adjusted indirect comparison (MAIC) study was conducted to compare the effectiveness of talquetamab… read more here.
Keywords: dosing schedules; talquetamab; sel dex; refractory multiple ... See more keywords